Sustained Remission of Pemphigus in Indian Patients with A Modified Lymphoma Rituximab Protocol

Abstract

AIM: Rituximab is a proven gratifying therapeutic modality for pemphigus of varying severity. While defined guidelines for its use in pemphigus are awaited, we treated patients with a modified lymphoma protocol of rituximab in an attempt to add on to the search for an ideal dosing schedule. MATERIALS AND METHODS: We studied retrospectively a total of 10 patients with pemphigus in a private practice setup offering facility of hospitalized care with rituximab as 10 infusions over a period of 7 months with a mean follow up period of 6 years. Patients had varying severity of disease and had not received rituximab in the past.